Shire PLC (LON:SHP)’s share price was up 0% during mid-day trading on Tuesday . The stock traded as high as GBX 3,725 ($50.52) and last traded at GBX 3,708.50 ($50.29). Approximately 2,760,000 shares changed hands during trading, an increase of 25% from the average daily volume of 2,200,000 shares. The stock had previously closed at GBX 3,708.50 ($50.29).
Several equities analysts have recently issued reports on SHP shares. Barclays restated an “equal weight” rating and set a GBX 4,000 ($54.24) price objective on shares of Shire in a report on Monday, October 30th. Shore Capital restated a “buy” rating on shares of Shire in a report on Thursday, October 26th. Goldman Sachs Group restated a “conviction-buy” rating on shares of Shire in a report on Tuesday, October 17th. Morgan Stanley cut their price objective on shares of Shire from GBX 5,800 ($78.65) to GBX 5,700 ($77.30) and set an “overweight” rating on the stock in a report on Thursday, October 12th. Finally, cut their price objective on shares of Shire from GBX 4,480 ($60.75) to GBX 4,050 ($54.92) and set a “hold” rating on the stock in a report on Tuesday, October 31st. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Shire currently has an average rating of “Buy” and a consensus target price of GBX 5,272.22 ($71.50).
The company has a market capitalization of $33,740.00 and a PE ratio of 2,830.92.
COPYRIGHT VIOLATION WARNING: “Shire (SHP) Trading Up 0%” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.themarketsdaily.com/2018/01/09/shire-shp-trading-up-0.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.